Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting System (FAERS).

Authors: Matthew Alexander Lunning, Marcela Valderrama Maus, Moataz Ellithi, Farah Toron, Robert Braun, Lin Wang, Pearl Wang, Maxwell Jones, Magdi Elsallab

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.7028

Source: Full article


Abstract

7028